SNX-482
(Synthetic peptide originally isolated from Tarantula, Hysterocrates gigas)

4363-s 0.1 mg | 285.00 EUR

Gly - Val - Asp - Lys - Ala - Gly - Cys - Arg - Tyr - Met - Phe - Gly - Gly - Cys - Ser - Val - Asn - Asp - Asp - Cys - Cys - Pro - Arg - Leu - Gly - Cys - His - Ser - Leu - Phe - Ser - Tyr - Cys - Ala - Trp - Asp - Leu - Thr - Phe - Ser - Asp

(M.W. 4495.0)

C192H274N52O60S7

Ca²⁺ channel blocker

SNX-482 is a well defined channel blocker, which belongs to the group of R-type (or class α1E) selective channel blockers. The peptide toxin SNX-482 was originally isolated from African spider venom and described from R. Newcomb at al as a complex polypeptide, composed of 41 amino acids including three disulfide bridges. It blocks oxytocin but not vasopressin release and reduces secretion of insulin. This synthetic channel blocker is often used in the research of pain transmission and in neuropathic pain models.
The Voltage-dependent channels from Ca²⁺ subtype plays well defined roles in the neurotransmitter release and other physiological functions.

Blocking activity of SNX-482

class E Ca channel	IC50 = 15-30 nM
R-type Ca current	40 nM
N-type Ca current	weakly blocked 30-50% at 300-500 nM

SNX-482 is a synthetic polypeptide, carefully manufactured and analized by Peptide Institute, Osaka. The purity of our product is guaranteed to be higher than 99% by HPLC.

Download PDF-data-sheet:

Shipping | Storage | Stability
Peptides from PetaNova will be shipped at room temperature directly from our store in Sandhausen, Germany. Information about product specific storage conditions will be found on the vial. Stock solutions should be stored at -20°C. Please avoid repeated freezing and thawing.

References:

1. R. Newcomb, B. Szoke, A. Palma, G. Wang, X.-h. Chen, W. Hopkins, R. Cong, J. Miller, L. Urge, K. Tarczy-Hornoch, J.A. Loo, D.J. Dooley, L. Nadasdi, R. W. Tsien, J. Lemos and G. Miljanich, Biochemistry, 37, 15353 (1998) (Original description)
2. A. Tottene, S. Volsen and D. Pietrobon, Biochemistry., 20, 171 (2000) (Pharmacol.)
3. J.G. Wang, G. Dayanithi, R. Newcomb, and J. R. Lemos, J. Neurosci., 19, 9235 (1999) (Pharmacology)